This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clovis Oncology Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

56.9%

Groei van de winst

53.1%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	48.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	13 Dec 2022

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

XTRA:C6O - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2024	389	-33	N/A	N/A	1
12/31/2023	249	-149	N/A	N/A	1
12/31/2022	154	-212	N/A	N/A	1
9/30/2022	133	-252	-176	-176	N/A
6/30/2022	140	-263	-181	-181	N/A
3/31/2022	145	-258	-193	-193	N/A
12/31/2021	149	-265	-196	-196	N/A
9/30/2021	156	-299	-211	-211	N/A
6/30/2021	157	-310	-219	-219	N/A
3/31/2021	160	-336	-241	-232	N/A
12/31/2020	165	-369	-261	-253	N/A
9/30/2020	161	-370	-275	-267	N/A
6/30/2020	159	-385	-279	-269	N/A
3/31/2020	152	-413	-311	-308	N/A
12/31/2019	143	-400	-343	-324	N/A
9/30/2019	134	-400	-356	-336	N/A
6/30/2019	119	-396	-376	-352	N/A
3/31/2019	110	-377	-444	-364	N/A
12/31/2018	95	-368	-430	-366	N/A
9/30/2018	82	-321	-412	-349	N/A
6/30/2018	76	-291	-380	-322	N/A
3/31/2018	67	-366	-282	-281	N/A
12/31/2017	56	-346	-265	-261	N/A
9/30/2017	39	-365	-254	-250	N/A
6/30/2017	22	-370	-268	-265	N/A
3/31/2017	7	-324	-267	-263	N/A
12/31/2016	0	-349	-267	-267	N/A
9/30/2016	N/A	-398	-290	-288	N/A
6/30/2016	N/A	-431	N/A	-299	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat C6O de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat C6O de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat C6O de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van C6O ( 48.6% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van C6O ( 48.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van C6O naar verwachting over 3 jaar hoog zal zijn

This company listing is no longer active

Clovis Oncology Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Now 20% undervalued after recent price drop

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Revenue beats expectations

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €8.10

New 90-day high: €4.77

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.78

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven